"Mary Crowley Cancer Research is a nonprofit 501(c)3 cancer research center that conducts clinical trial testing of the newest cancer discoveries, operating in compliance with the Food and Drug Administration (FDA) guidelines for over 20 years. Mary Crowley offers: • A personalized approach to cancer research • Phase I and Phase II clinical trials matched to molecular information found within each cancer patient •Qualified Physician Investigators who add to the understanding of what drives cancer and create innovative research applications that attack these drivers •A patient-centric focus bringing clinical trial options to patients at a rapid pace"

During the past decade, Mary Crowley Cancer Research Centers - Medical City conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mary Crowley Cancer Research Centers - Medical City" #1 sponsor was "Xencor, Inc." with 2 trials, followed by "Aduro Biotech, Inc." with 1 trials sponsored, "Amgen" with 1 trials sponsored, "Celgene" with 1 trials sponsored and "Celldex Therapeutics" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mary Crowley Cancer Research Centers - Medical City" #1 collaborator was "Hanlee P. Ji, MD" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "ICON plc" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Mary Crowley Cancer Research Centers - Medical City" are "Advanced Solid Tumors" (2 trials), "Cervical Carcinoma" (2 trials), "Cholangiocarcinoma" (2 trials), "Colorectal Carcinoma" (2 trials) and "Endometrial Carcinoma" (2 trials). Many other conditions were trialed in "Mary Crowley Cancer Research Centers - Medical City" in a lesser frequency.

Most popular intervention types in "Mary Crowley Cancer Research Centers - Medical City" are "Drug" (9 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "A166" (1 trials), "CC-223, erlotinib" (1 trials), "CC-223, oral azacitidine" (1 trials), "CDX-1127" (1 trials) and "Futibatinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mary Crowley Cancer Research Centers - Medical City" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Mary Crowley Cancer Research Centers - Medical City". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Mary Crowley Cancer Research Centers - Medical City, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Mary Crowley Cancer Research Centers - Medical City, 12 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".